KnowTheStock
Log inCreate free account

REGENERON PHARMACEUTICALS, INC.

REGN
S&P 500Nasdaq 100Pharmaceutical Preparations · Nasdaq
$750.51last close · market cap 79.25 Billion
Compare with…
73.4SCORE / 100
Our verdictSELLStrong Growth and Stable, Stock Price Very HighQtr Ending 2026-09-30

Why Sell

Income statement and balance sheet are strong; cash flow is moderate.

Next earnings: 2026-10-30 (BMO), EPS Forecast: $13.76

What is strong
  • Revenue Growth is 18.59%
  • Operating Income Growth is 31.89%
  • Net Margin is 28.51%
  • Current Asset to Current Liability Ratio is 3.35
  • Debt Ratio is 0.25
  • Current Debt to Net Income Ratio is 0.0
  • Total Debt to Total Assets Ratio is 0.04
  • Capital Expenditure is Low
  • Net Increase in Cash is Positive
What to watch
  • Net Income Growth is 5.23%
  • Earnings Per Share (EPS) Growth is 8.92%
  • Cash from Operations Growth is -4.44%
  • Investment Risk is High

What changed

Score by quarter

Downgraded from Hold to Sell in the Sep 2025 quarter: 70.9 → 68.9 (-2.0). This quarter: +4.8.

607080Mar 2023Sep 2026

What the score is made of

Income statement68.2 +8.7
Balance sheet96.3 +0.0
Cash flow49.2 +0.0

Change vs previous quarter.

Key numbers · latest quarter

Revenue (TTM)16.90 Billion18.59 % growth
EPS45.318.92 % growth
Profit margin28.51 %Profit per $1 of sales
P-E ratio—Not available
Market cap79.25 BillionShares × price
Debt-equity ratio0.06Leverage
Dividend3.70Per share, annual
Next earnings2026-10-30BMO · EPS forecast $13.76
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.

About REGENERON PHARMACEUTICALS, INC.

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

CEO
Leonard Schleifer
Employees
12,099
Sector
Manufacturing
Exchange
Nasdaq
regeneron.com

Similar stocks

Loading…